Dual-Target siRNA: the Future of RNAi Therapeutics

On September 15, 2026, Arrowhead Pharmaceuticals released interim Phase 1/2a clinical data for ARO-DIMER-PA that could fundamentally reshape cardiometabolic drug design. The results represent a critical milestone: the clinical validation of a dual-functional RNAi dimer, a single investigational siRNA molecule engineered to simultaneously silence two distinct genes, PCSK9 and APOC3 ^[1]. For anyone developing next-generation lipid-lowering therapies, this readout deserves close attention.

Figure 1. Schematic design of ARO-DIMER-PA ^[1].

The interim data demonstrated that a single dose achieved profound, dual-pathway suppression. Mean maximum reductions included:

• Target Silencing: ~72% reduction in serum PCSK9 and ~88% reduction in serum APOC3.
• Lipid Impact: 54% reduction in LDL-C, 73% reduction in triglycerides, and a 50% reduction in ApoB.

According to Arrowhead, this marks the first clinical validation of their platform’s ability to achieve robust dual-target gene silencing using a single molecule ^[2].

These are early numbers from an interim readout, and durability, safety, and larger patient cohorts will ultimately determine the program's future. Even so, the data move dual-target RNAi from concept into human clinical evidence, with direct implications for how combination lipid-lowering therapy may be designed for cardiovascular disease.

Why Dual-Target siRNA Matters for Drug Development

Cardiovascular disease rarely comes down to a single abnormal lipid. Many high-risk patients live with mixed dyslipidemia, which means elevated LDL-C along with high triglycerides and triglyceride-rich remnant lipoproteins ^[3]. Even when LDL-C is driven down with statins and PCSK9 inhibitors, a meaningful share of cardiovascular risk remains ^[4]. Much of this residual cardiovascular risk tracks with ApoB-containing particles that LDL-lowering alone doesn't fully address ^[5].

Figure 2. The evolving therapeutic landscape of PCSK9 inhibition ^[6].

The conventional answer is polypharmacy: one drug for LDL-C, another for triglycerides, each with its own dosing schedule, cost, and adherence burden. Anyone who has studied real-world persistence on chronic cardiovascular therapy knows how quickly that stack erodes ^[7]. Patients stop filling prescriptions, miss injections, or never start the second agent at all ^[8].

A dual-target siRNA offers a different path. Because GalNAc-conjugated siRNAs already achieve months-long gene knockdown in the liver from a single subcutaneous injection ^[9], combining two silencing payloads into one molecule could deliver two mechanisms of action on one infrequent dosing schedule. For patients, that means fewer injections. For drug developers, it means one clinical program and one manufacturing process instead of two. It also opens a scientific door: pairing complementary hepatic targets that were never practical to combine as separate products.

PCSK9 and APOC3: Complementary Targets for Broader Lipid Control

PCSK9 and APOC3 are two genetically and clinically validated targets that regulate different components of atherogenic lipid metabolism. PCSK9 inhibition increases hepatic LDL receptor availability to lower LDL-C, while APOC3 silencing enhances the clearance of triglyceride-rich lipoproteins and their remnants.

Figure 3. The targets for gene therapy in the treatment of hyperlipidemia ^[10].

Although PCSK9-targeted therapies have demonstrated meaningful cardiovascular benefit, broader use has been limited by treatment burden, access, and their focus on a single lipid pathway. APOC3-targeting therapies can produce substantial triglyceride reductions, but clinical development has so far been concentrated largely in severe hypertriglyceridemia and rare lipid disorders ^[11]. Combining both mechanisms in a single molecule could therefore address LDL-C and triglyceride-rich particles simultaneously, reducing ApoB-containing lipoprotein burden through complementary pathways. Early data showing approximately 50% ApoB and 61% non-HDL-C reductions support the potential of this dual-targeting strategy for patients with mixed dyslipidemia and residual cardiovascular risk ^[2].

Dual-Target RNAi vs. Bispecific Antibodies

Delivering two mechanisms in a single agent is also the rationale behind bispecific antibodies, currently the most established dual-target modality. Each approach has distinct strengths, and comparing them shows where dual-target RNAi is likely to be most competitive.

Table 1. Comparison of Dual-Target Modalities.

The long-acting nature of the knockdown means that adverse effects cannot be rapidly reversed. Furthermore, combining two payloads introduces fixed knockdown ratios, compounded off-target risks from two distinct sequences ^[12], and a more complex regulatory pathway.

Ultimately, the future is not winner-take-all. Dual-target RNAi is well positioned to disrupt chronic, liver-driven diseases where durability and patient adherence are paramount. Bispecific antibodies will likely remain important in oncology, immunology, and settings where targets are expressed outside the liver or therapeutic activity depends on protein-level interactions.

Why Humanized Mouse Models Are Non-Negotiable

For developers racing to enter the dual-target RNAi space, a critical preclinical bottleneck has emerged. siRNA activity is sequence-specific. A molecule designed against human PCSK9 and human APOC3 transcripts may not engage the mouse orthologs at all, which makes standard wild-type mice a poor system for testing clinical siRNA candidates. Evaluating a dual-target drug properly requires a humanized mouse model that expresses both human targets in the same animal.

HUGO-GT™ humanized mouse models can also serve as building blocks for more complex study designs. Through breeding or direct genome editing, humanized alleles can be combined with additional humanized genes, disease-associated mutations, knockout or knock-in alleles, and other engineered backgrounds. This enables tailored models that better match specific disease biology and therapeutic mechanisms.

Our huPCSK9/huAPOC3-Tg double-humanized mouse (C001744) is a direct example. Created by crossing huPCSK9 mice with huAPOC3-TG mice on a C57BL/6N background, this model expresses both human PCSK9 and human ApoC-III. It is designed for preclinical evaluation of siRNA, ASO, and antibody therapeutics against either target alone or both together, and it supports research in hypercholesterolemia, hypertriglyceridemia, and atherosclerosis.

Figure 5. Changes in serum human PCSK9 protein levels in huPCSK9 mice treated with siRNA drugs (6-week-old, male, serum)*.

*The four siRNA drugs (PC1, PC2, PC3, PC4), supplied by the client, are designed to inhibit hPCSK9 expression.

Beyond PCSK9/APOC3: Building Models for Multi-Target RNAi Programs

The same principle extends well beyond the PCSK9/APOC3 pairing. Any dual-target siRNA program requires both human targets to be present in the same animal for meaningful in vivo evaluation of knockdown, target engagement, and downstream pharmacology. Cyagen has built a portfolio of double-humanized mouse models covering a range of target combinations, and new combinations can be generated by crossing existing humanized lines or by direct genome editing. As multi-target RNAi advances further into the clinic, such models will be increasingly important for candidate selection, for comparing single- versus dual-target knockdown, and for de-risking programs before first-in-human studies.

👉 [Explore Our HUGO-GT™ humanized mouse models suitable for siRNA researches]

👉 [Discuss Your Next Preclinical Study with Our Experts]

Reference

[1] Van Dyke J, Branca-Afrazi M, Glebocka A, Klossowski S, McBride Z, Chen J, Hamilton H, Pei T, Hamilton J, Ding ZM. Development of a dual functional RNAi therapeutic, ARO-DIMER-PA, for mixed hyperlipidemia. J Clin Lipidol. 2025;19(3 Suppl):e111-e112. doi:10.1016/j.jacl.2025.04.160.

[2] Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals initiates Phase 1/2a study of ARO-DIMER-PA: the first dual functional RNAi therapeutic for the treatment of mixed hyperlipidemia [Internet]. Pasadena (CA): Arrowhead Pharmaceuticals, Inc.; 2026 Jan 27 [cited 2026 Sep 23]. Available from: https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-initiates-phase-12a-study-aro-dimer-pa

[3] Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokgözoğlu LS, Tybjaerg-Hansen A, Stock JK, Catapano AL. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021 Dec 14;42(47):4791-4806. doi: 10.1093/eurheartj/ehab551. PMID: 34472586; PMCID: PMC8670783.

[4] Vijayaraghavan K, Baum S, Desai NR, Voyce SJ. Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins. Front Cardiovasc Med. 2024 Jan 15;10:1308173. doi: 10.3389/fcvm.2023.1308173. PMID: 38288054; PMCID: PMC10822878.

[5] Lee JH, Ahn SG, Jeon HS, Lee JW, Youn YJ, Lee YJ, Lee SJ, Hong SJ, Ahn CM, Ko YG, Kim JS, Choi D, Hong MK, Jang Y, Kim BK. Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial. J Clin Lipidol. 2024 Nov-Dec;18(6):e905-e914. doi: 10.1016/j.jacl.2024.07.005. Epub 2024 Jul 27. PMID: 39322526.

[6] Mansfield BS, Bene-Alhasan Y, Ballantyne CM, Raal FJ. The evolving therapeutic landscape of PCSK9 inhibition. Atherosclerosis. 2026 Mar;414:120670. doi: 10.1016/j.atherosclerosis.2026.120670. Epub 2026 Feb 9. PMID: 41687316.

[7] LaFratte C, Peasah SK, Huang Y, Hall D, Patel U, Good CB. Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation. J Am Heart Assoc. 2023 Sep 19;12(18):e029707. doi: 10.1161/JAHA.123.029707. Epub 2023 Sep 13. PMID: 37702065; PMCID: PMC10547275.

[8] Parhofer KG, Pittrow D, Birkenfeld AL, Fraass U, Hohenstein B, Siegert C, Klotsche J, Steinhagen-Thiessen E, Dexl S, Schettler VJJ, Laufs U. Treatment persistence, lipid lowering, and 3-year clinical outcomes in patients at very high cardiovascular risk on PCSK9 monoclonal antibodies. Clin Res Cardiol. 2026 Feb;115(2):288-303. doi: 10.1007/s00392-025-02719-z. Epub 2025 Aug 4. PMID: 40760109; PMCID: PMC12823742.

[9] Brown CR, Gupta S, Qin J, Racie T, He G, Lentini S, Malone R, Yu M, Matsuda S, Shulga-Morskaya S, Nair AV, Theile CS, Schmidt K, Shahraz A, Goel V, Parmar RG, Zlatev I, Schlegel MK, Nair JK, Jayaraman M, Manoharan M, Brown D, Maier MA, Jadhav V. Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates. Nucleic Acids Res. 2020 Dec 2;48(21):11827-11844. doi: 10.1093/nar/gkaa670. PMID: 32808038; PMCID: PMC7708070.

[10] Wu T, Hu Y, Tang LV. Gene therapy for polygenic or complex diseases. Biomark Res. 2024 Sep 4;12(1):99. doi: 10.1186/s40364-024-00618-5. PMID: 39232780; PMCID: PMC11375922.

[11] Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, Soran H, Prohaska TA, Xia S, Ginsberg HN, Witztum JL, Tsimikas S; Balance Investigators. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024 May 16;390(19):1781-1792. doi: 10.1056/NEJMoa2400201. Epub 2024 Apr 7. PMID: 38587247.

[12] Janas MM, Schlegel MK, Harbison CE, Yilmaz VO, Jiang Y, Parmar R, Zlatev I, Castoreno A, Xu H, Shulga-Morskaya S, Rajeev KG, Manoharan M, Keirstead ND, Maier MA, Jadhav V. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun. 2018 Feb 19;9(1):723. doi: 10.1038/s41467-018-02989-4. PMID: 29459660; PMCID: PMC5818625.